Cost of Retinal Blindness Will Be in the Billions by 2020, Speaker Says

Cost of Retinal Blindness Will Be in the Billions by 2020, Speaker Says

Most of the cost will be from age-related macular degeneration (AMD).

The direct, indirect, and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy is estimated to cost the U.S. approximately $21 billion by 2020, according to a speaker at the Retina World Congress in Fort Lauderdale, Florida, Healio.com reports.

“Age-related macular degeneration will constitute the lion’s share of this amount with a little over $16 billion. Diabetic retinopathy will be about $4.5 billion,” Andrew A. Moshfeghi said at the meeting.

Dr. Moshfeghi said that if management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) did not improve, the costs associated with these diseases could triple by 2050.

Read the full story:

How To Qualify